Brief Communication

Clinical impact of antibody formation to botulinum toxin A in children

  1. Jochen Herrmann MD1,
  2. Katrin Geth MD2,
  3. Volker Mall MD2,
  4. Hans Bigalke MD3,
  5. Jürgen Schulte Mönting PhD4,
  6. Michaela Linder MD2,
  7. Jan Kirschner MD2,
  8. Steffen Berweck MD5,
  9. Rudolf Korinthenberg MD2,
  10. Florian Heinen MD5,*,
  11. Urban M. Fietzek MD5

Article first published online: 26 APR 2004

DOI: 10.1002/ana.20098

Issue

Annals of Neurology

Annals of Neurology

Volume 55, Issue 5, pages 732–735, May 2004

Additional Information

How to Cite

Herrmann, J., Geth, K., Mall, V., Bigalke, H., Schulte Mönting, J., Linder, M., Kirschner, J., Berweck, S., Korinthenberg, R., Heinen, F. and Fietzek, U. M. (2004), Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol., 55: 732–735. doi: 10.1002/ana.20098

Author Information

  1. 1

    Department of Pediatric Radiology, University Clinic Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany

  2. 2

    Department of Neuropediatrics and Muscle Disease, University of Freiburg, Mathildenstrasse 1, D-79106 Freiburg, Germany

  3. 3

    Institute of Toxicology, Medical School of Hannover, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany

  4. 4

    Institute of Medical Biometry and Medical Informatics, University of Freiburg, Stefan-Meier-Strasse 26, D-79104 Freiburg, Germany

  5. 5

    Department of Pediatric Neurology and Developmental Neuroscience, Dr. von Hauner's Children's Hospital, University of Munich, Lindwurmstrasse 4, D-80337 Munich, Germany

*Department of Pediatric Neurology and Developmental Neuroscience, Dr. von Hauner's Children's Hospital of the University of Munich, Lindwurmstrasse 4, D-80337, Munich Germany

Publication History

  1. Issue published online: 26 APR 2004
  2. Article first published online: 26 APR 2004
  3. Manuscript Accepted: 25 FEB 2004
  4. Manuscript Revised: 23 FEB 2004
  5. Manuscript Received: 2 DEC 2003

Funded by

  • PharmAllergan GmbH, Ettlingen, Germany
  • Merz Pharmaceuticals
  • Ipsen Pharma

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (68K)

Abstract

We studied the clinical impact of neutralizing antibodies to botulinum toxin A that occurred during long-term treatment of children between 1993 and 2001. Antibodies were found in high titers in 35 of 110 (31.8%) samples from individual patients. Antibody formation correlated with secondary nonresponse (p < 0.001). The most significant risk factors for antibody formation were the frequency of treatments (p = 0.0001) and the injection of a higher weight-adapted maximum dose per treatment (p = 0.001).

View Full Article (HTML) Get PDF (68K)